此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

漆黄素可改善老年人的血管功能

2026年9月22日 更新者:Matthew Rossman、University of Colorado, Boulder

漆黄素 Senolytic 疗法改善老年人血管功能的临床转化

This is a pilot clinical trial to test the efficacy of intermittent treatment with the flavonoid compound fisetin for improving vascular endothelial function and reducing aortic stiffness in older adults. This trial will also determine the potential mechanisms by which fisetin may improve vascular function, including by decreasing mitochondrial oxidative stress, cellular senescence and senescence-associated secretory phenotype (SASP) factors in circulation. Lastly, safety, tolerability and adherence of fisetin treatment will be assessed.

研究概览

详细说明

Cellular senescence increases with aging and contributes to physiological dysfunction. Studies in animal models show that the flavonoid compound fisetin is an effective treatment for reducing cellular senescence and improving vascular function with aging. No published studies have used fisetin to target cellular senescence in older adults to improve vascular function. In addition, the biological reasons (mechanisms) by which fistin may improve vascular function in older adults has not been assessed. This study will evaluate if intermittent treatment with fisetin in older adults improves vascular function, reduces biological markers of cellular senescence, oxidative stress and inflammatory factors produced by senescent cells (i.e., senescence-associated secretory phenotype factors). The study will also evaluate safety, tolerability and adherence with fisetin treatment.

研究类型

介入性

注册 (估计的)

70

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Colorado
      • Boulder、Colorado、美国、80305
        • University of Colorado Boulder

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

65年 及以上 (年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age 65 years or older
  • Women must be postmenopausal
  • Body mass index (BMI) <40 kg/m2
  • Willing to accept random assignment
  • Weight stable in the prior 2 months (<2 kg weight change) and willing to remain weight stable throughout the study
  • Ability to understand study procedures and to comply with them for the entire length of the study
  • No blood donation within 8 weeks prior to baseline testing; willingness to abstain from blood donation during the study and for 8 weeks after study completion
  • Absence of established, serious, unstable, chronic clinical disease (e.g., unstable CVD) as determined by study physician of record based on subject medical history, physical examination, resting ECG and standard clinical blood chemistries

Exclusion Criteria:

  • Inability to refrain from alcohol for 24 hours prior to outcome assessment
  • Individuals taking fisetin, quercetin, luteolin, Dasatinib, piperlongumine or Navitoclax (supplements or drugs with established senolytic effects) within 6 months prior to baseline testing; should new research reveal other dietary supplements or drugs with potential senolytic effects, their use will be evaluated, and their use may lead to exclusion of the subject by the PI
  • New use of regular cardiovascular-acting medication which, in the opinion of the PI, affects the outcomes of the study within 3 months prior to starting baseline testing as reported during medication review during screening (these individuals could be enrolled after 3 months of regular use)
  • Chronic use of a dietary supplement which, in the opinion of the PI, affects the outcomes of the study, within 1 month prior to starting baseline testing as reported during medication review during screening (these individuals could be enrolled after 1 month of regular use)
  • Active malignancy (including myeloma) or malignancy that was active within 5 years prior to baseline testing
  • Inability or unwillingness of individual to give written informed consent
  • Current or past participation within 3 months in another clinical trial that, in the opinion of the PI, would affect the outcomes of the study
  • Known hypersensitivity or allergy to fisetin
  • Blood donation within 2 months prior to baseline testing
  • Resting blood pressure >160 mmHg systolic or >110 mmHg diastolic
  • Regular vigorous aerobic/endurance exercise

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
有源比较器:Fisetin

Fisetin will be administered in an intermittent manner with two, three-day dosing periods at a dose of 2 mg/kg/day separated by two weeks.

Fisetin dietary supplement

安慰剂比较:Placebo

Placebo capsules identical in appearance to fistin capsules will be administered in an intermittent manner with two, three-day dosing periods separated by two weeks.

Placebo capsules identical in appearance to fisetin capsules

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change from baseline in endothelial function at 1 month
大体时间:1 month

Brachial artery flow-mediated dilation

1 month

次要结果测量

结果测量
措施说明
大体时间
Change from baseline in aortic stiffness at 1 month
大体时间:1 month

Carotid-femoral pulse wave velocity

1 month

其他结果措施

结果测量
措施说明
大体时间
Change from baseline in suppression of endothelial function by mitochondrial oxidative stress at 1 month
大体时间:1 month

Change in brachial artery flow-mediated dilation with acute, supratherapeutic MitoQ (160mg)

1 month
Change from baseline in endothelial cell markers of cellular senescence at 1 month
大体时间:1 month

Endothelial cell abundance of p16 and p21

1 month
Change from baseline in blood cell markers of cellular senescence at 1 month
大体时间:1 month

p16-positive T-cells

1 month
Change from baseline in plasma markers of the senescence-associated secretory phenotype
大体时间:1 month

Circulating pro-inflammatory cytokines and chemokines

1 month

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Matthew J Rossman, PhD、University of Colorado, Boulder

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年9月25日

初级完成 (实际的)

2026年3月31日

研究完成 (估计的)

2027年3月31日

研究注册日期

首次提交

2023年11月10日

首先提交符合 QC 标准的

2023年11月10日

首次发布 (实际的)

2023年11月15日

研究记录更新

最后更新发布 (实际的)

2026年9月25日

上次提交的符合 QC 标准的更新

2026年9月22日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • 23-0288

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅